Should the federal government regulate access to abortion pills, or should that be left to individual states?

Background

Mifepristone, one of two drugs in the most common medication abortion regimen, has been at the center of an intensifying legal and political battle over whether the federal government or individual states should control access to abortion pills. The FDA approved mifepristone in 2000, and in 2023 the Biden administration finalized rules allowing it to be prescribed via telehealth and mailed to patients. According to the Guttmacher Institute, medication abortions accounted for 63 percent of all abortions in states without total bans in 2023, and roughly one in four abortions nationally now occur through telehealth. The debate escalated in May 2026 when the Fifth U.S. Circuit Court of Appeals blocked the mailing of mifepristone nationwide and required it to be distributed only in person at clinics, a ruling now before the U.S. Supreme Court on emergency appeal. Meanwhile, the Trump administration's FDA is conducting its own safety review of the drug, and multiple Republican-led states including Louisiana, Texas, and Missouri have pursued further restrictions through legislation and litigation.

Supporters of federal regulation argue that the FDA is best positioned to set uniform, science-based rules for drug safety and access. Pharmaceutical companies and medical organizations such as the American College of Obstetricians and Gynecologists and the American Medical Association have affirmed that mifepristone's safety is supported by decades of clinical research and real-world data. Those favoring continued federal oversight warn that allowing each state to set its own rules could fragment pharmaceutical regulation in unprecedented ways and, as drugmakers have argued, upend the broader drug approval process. On the other side, proponents of state authority contend that the 2022 Dobbs decision returned abortion policy to the states, and that federal rules allowing pills to be mailed effectively override state abortion bans. Louisiana, the lead plaintiff in the current case, argues that telehealth prescriptions enable hundreds of abortions within its borders each year in defiance of state law. Several Republican-led states have also pursued their own restrictions, including scheduling mifepristone as a controlled substance and pursuing criminal cases against out-of-state prescribers.

The outcome of this debate could reshape reproductive healthcare access for millions of Americans. If the Supreme Court allows the Fifth Circuit's restrictions to stand, patients in every state — not just those with abortion bans — would lose the ability to obtain mifepristone through telehealth or by mail. Rural patients and those in states with few clinics would be disproportionately affected. The case also raises broader questions about the FDA's authority to regulate drugs based on scientific evidence versus states' power to restrict medications for policy reasons. With abortion-related ballot measures heading to voters in multiple states in November 2026, and polling from the Public Religion Research Institute showing shifting voter priorities around reproductive rights, the legal and political resolution of this question will likely influence both healthcare access and the midterm elections.